Vesalius Biocapital Partners
Overview
Vesalius Biocapital Partners is a European life sciences venture capital investor. They invest in companies active in human health through venture capital funds raised since 2007, focusing on therapeutics, medical devices & diagnostics and eHealth / mHealth. They finance both early stage companies and corporate spin-offs with more mature assets.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Sword Health | Feb 2021 | Series B | Co-investor |
| ENYO Pharma | Jun 2025 | Series C Extension | Lead |
| OMEICOS Therapeutics | Nov 2018 | Series C | Co-investor |
| Complix N.V. | Jun 2013 | Series B | Co-investor |
| inHEART | May 2024 | Early Funding | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Vesalius Biocapital Partners based?
Vesalius Biocapital Partners is headquartered in Strassen, Canton of Luxembourg, Luxembourg.
When was Vesalius Biocapital Partners founded?
Vesalius Biocapital Partners was founded in 2007.
How many portfolio companies does Vesalius Biocapital Partners have?
Vesalius Biocapital Partners has 23 portfolio companies in Caplight's dataset.
What are some companies in Vesalius Biocapital Partners's portfolio?
Portfolio companies visible on Caplight include Sword Health, ENYO Pharma, OMEICOS Therapeutics, Complix N.V., inHEART.
What was Vesalius Biocapital Partners's most recent investment shown here?
Vesalius Biocapital Partners's most recent investment in this portfolio sample was in ENYO Pharma in 2025.
What sectors does Vesalius Biocapital Partners focus on?
Vesalius Biocapital Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure, Enterprise Software.
What company stages does Vesalius Biocapital Partners focus on?
Vesalius Biocapital Partners typically invests at the MultiStage stage.
What is Vesalius Biocapital Partners's AUM?
Vesalius Biocapital Partners's assets under management are estimated between $100.0M and $250.0M.